Insight Molecular Diagnostics Inc. (IMDX) stock intrinsic value fair value estimate & owner earnings analysis

Insight Molecular Diagnostics develops blood tests that monitor rejection in transplanted organs. Its main products are the GraftAssure family of kitted tests, which run on digital PCR instruments made by Bio-Rad Laboratories. Bio-Rad is also a shareholder, and the two companies have a global partnership signed in April 2024. The company also earns revenue from laboratory services for outside customers, which it expects to shrink as it shifts its sales effort to the kits. It previously sold its DetermaRx testing business in what it calls the Razor sale transaction. Almost all revenue is in the United States. What the business earns today. Revenue was about $4.1 million in 2025, up from $1.9 million in 2024, against operating spending in 2025 of roughly $15.9 million for research, $6.3 million for sales and marketing and $10.6 million for general and administrative costs. Cash used in operations was $22.2 million in 2025 and $20.7 million in 2024. We measure owner earnings as operating cash flow, less the cash effect of working-capital swings, less stock-based compensation, less the part of equipment spending needed just to stand still. On that basis owner earnings were about negative $29.2 million in 2025 (about negative $0.96 per share) and about negative $21.5 million in 2024 (about negative $1.64 per share). The losses are not an accounting artifact: after adding back the large non-cash items (a $14.6 million impairment and a $5.9 million increase in the contingent-consideration liability in 2025; a $41.9 million impairment in 2024), the cash outflow is still real, and the company has an accumulated deficit of $400.8 million. Repeated write-downs of past acquisitions are part of the picture. Because owner earnings are negative and there is no year of positive earnings to anchor on, there is no earnings level to grow from. The most recent half-year points the same way: cash used in operations was $16.9 million for the first six months of 2026, while reported revenue for those six months was $0.27 million. Bear, base and bull. All three cases are worth $0 per share. The company's main hope is GraftAssureDx, the kitted version of its transplant rejection test, for which the company submitted a data package to the FDA on March 25, 2026 seeking marketing authorization. An authorization decision, and any sales that follow, have not yet happened, and revenue from the kits is still small compared with the cost of running the company. Under our method, growth is only counted when it is contracted or is the continuation of something the business has already done repeatedly; new products, share gains and turning a loss into a profit do not qualify. So the bull case does not include a successful FDA outcome, and no case credits a profit the company has not yet shown. This is a statement about what can be evidenced today, not a claim that the company cannot succeed. A reader who believes in the test is making a bet on future events that we cannot value from the filings. Funding. In February 2026 the company raised about $26.0 million before fees by selling 3,482,498 shares and pre-funded warrants for 1,043,478 shares at $5.75 each, and in its annual report management concluded that doubt about continuing as a going concern no longer existed. Cash and equivalents were $17.8 million on June 30, 2026, against $16.9 million of operating cash used in the first half of that year. At that pace the current cash covers only about six months of spending, so additional capital will likely be needed soon, and past raises (Bio-Rad, Broadwood and AWM-affiliated entities took part in the February 2026 raise) have diluted existing shareholders. We could not review the wording of the June 2026 quarterly report, so this funding view rests on the annual report and the reported cash figures. What could make this wrong. If the FDA authorizes GraftAssureDx and kit sales grow quickly enough to cover the roughly $33 million a year of operating costs (2025 research, sales and marketing, and general and administrative spending combined), the shares would be worth something; today that is not something we can evidence. We attempted to challenge our own conclusion with the strongest available fact: 2025 revenue more than doubled to $4.1 million with the first kitted-product revenue. But the same year's cash burn did not fall, and revenue for the first half of 2026 was well below the first half of 2025, so the growth did not translate into a path to positive owner earnings. Margin-of-safety price. Because we cannot assign value to the business as it stands, there is no margin-of-safety price above zero. The estimate would be revisited once operating cash flow, after stock compensation and equipment spending, turns and stays positive.